Skip to Content
Merck
All Photos(2)

Key Documents

More Documents

94497

Supelco

Norgestimate

analytical standard

Synonym(s):

(17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime, Dexnorgestrel acetime

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C23H31NO3
CAS Number:
35189-28-7
Molecular Weight:
369.50
Beilstein:
6440219
UNSPSC Code:
41116107
NACRES:
NA.24

grade

analytical standard

Quality Level

100

Assay

≥99.0% (HPLC)

optical activity

[α]/D 43±3°, c = 1 in chloroform

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

clinical testing

format

neat

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N/O)[C@@H]1CC[C@@]2(OC(C)=O)C#C

InChI

1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1

InChI key

KIQQMECNKUGGKA-NMYWJIRASA-N

Looking for similar products? Visit Product Comparison Guide

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictograms

Exclamation markHealth hazard
GHS07,GHS08

Signal Word

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCBH7058V
BCBH7058

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Susan Jick et al.
Contraception, 76(1), 4-7 (2007-06-26)
In 2006, we published a study that indicated that the new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin did not increase the risk for venous thromboembolism (VTE) compared to oral contraceptive containing norgestimate and 35 microg
Julia V Johnson et al.
Obstetrics and gynecology, 111(2 Pt 1), 278-284 (2008-02-02)
To compare the effects of oral and transdermal contraceptives containing similar hormone formulations on vascular risk markers. We conducted a randomized, investigator-blinded, crossover, clinical trial with 24 healthy women, aged 18-35 years, who received 2 months of transdermal or oral
Ronald T Burkman et al.
Contraception, 79(6), 424-427 (2009-05-16)
This analysis investigated the association of oral contraceptive efficacy with body weight and body mass index (BMI) for hypothesis-generating purposes. Data were from a randomized, parallel-group trial of 180/215/250 mcg of norgestimate (NGM)/25 mcg of ethinyl estradiol (EE) (given to
Matt S Anderson et al.
British journal of clinical pharmacology, 71(4), 616-620 (2011-03-15)
Oral contraceptives such as norgestimate-ethinyl estradiol (Ortho Tri-Cyclen®) are commonly prescribed in the HIV-infected patient population. A placebo-controlled, randomized, two-period crossover study in healthy HIV-seronegative subjects was conducted to assess the effect of raltegravir on the pharmacokinetics of the estrogen
Teri Greco et al.
Contraception, 76(1), 8-17 (2007-06-26)
This study compared two oral contraceptives (OCs) with the same triphasic regimen of progestin (norgestimate 0.18, 0.215 and 0.25 mg) but differing doses of ethinyl estradiol (EE) - 25 and 35 microg EE - in their effects on androgens, mood
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service